Skip to main content
. 2022 Apr 3;14(4):783. doi: 10.3390/pharmaceutics14040783

Figure 12.

Figure 12

Cytotoxicity profiles of the optimized AGN-PLHNPs against (A) MCF-10A and (B) 3T3 non-neoplastic cells after 24 h, 48 h, and 72 h.

HHS Vulnerability Disclosure